Autopsy report · NCT01489319

Evaluation of Oral Lipid Ingestion in Relation to Ovarian Androgen Secretion in Polycystic Ovary Syndrome (PCOS)

“The PI left Indiana University. The findings served as preliminary data for a recently awarded NIH R01 grant.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 2 months before it started.
• Ran for about 3 years 4 months before it stopped.
• 47 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1

Sponsor

Indiana University

Sponsor type

University, hospital or other

Conditions

Polycystic Ovary Syndrome

Interventions

Salsalate; Salsalate

Participants

47

Sites

1

Countries

United States

Trials that died the same way

• Ribociclib and Gemcitabine Hydrochloride in Treating Patients With Advanced Solid Tumors or Lymphoma
  “PI left institute” (68% match in meaning)
• Erlotinib and Standard Platinum-Based Chemotherapy for Newly Diagnosed, Advanced Non-Small Cell Carcinoma of the Lung
  “PI left institution.” (66% match in meaning)
• Pulse Wave Analysis in Advanced Heart Failure
  “PI left University” (65% match in meaning)
• Ketamine in Patients Undergoing Anterior Cervical Discectomy and Fusion
  “PI has left the University” (65% match in meaning)
• Cilostazol After Lower Extremity Arterial Revascularization Trial
  “Original PI left institution” (64% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.